Overview

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia

Status:
Completed
Trial end date:
2015-10-12
Target enrollment:
Participant gender:
Summary
This is an international observational study in patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism.
Details
Lead Sponsor:
Bayer
Collaborator:
Janssen Research & Development, LLC
Treatments:
Rivaroxaban